# A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05518045/  
OnCo record `nct05518045` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of LM-108 and Toripalimab in advanced solid tumours, run by LaNova Medicines Limited, active and no longer recruiting.

## Summary

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05518045 by LaNova Medicines Limited, with 392 participants enrolled, started 2022-08-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: LM-108 and Toripalimab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05518045
- Phase: 1/2
- Setting: An Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108 for Injection as Monotherapy or in Combination With Antitumor Therapies in Patients With Advanced Solid Tumors
- Sponsor: LaNova Medicines Limited
- Enrolled: 392

## Sources

- ClinicalTrials.gov NCT05518045: https://clinicaltrials.gov/study/NCT05518045

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [LM-108](https://onco.cc/drugs/lm-108/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- companies: [LaNova Medicines](https://onco.cc/companies/lanova-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct05518045.json